Publish-box (todo)
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative |
Raw Turtle (+ also see Turtle/RDF Format Specification)
Definition for Code SystemResearchStudyPhase
@prefix fhir: <http://hl7.org/fhir/> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . # - resource ------------------------------------------------------------------- [] a fhir:CodeSystem ; fhir:id [ fhir:v "research-study-phase"] ; fhir:meta [ fhir:lastUpdated [ fhir:v "2024-08-12T19:52:12.437+11:00" ] ; fhir:profile ( [ fhir:v "http://hl7.org/fhir/StructureDefinition/shareablecodesystem" ] ) ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ] ; fhir:extension ( [ fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg" ] ; fhir:value [ fhir:v "brr" ] ] [ fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status" ] ; fhir:value [ fhir:v "trial-use" ] ] [ fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm" ] ; fhir:value [ fhir:v "0" ] ] ) ; fhir:url [ fhir:v "http://hl7.org/fhir/research-study-phase"], [ fhir:v "http://hl7.org/fhir/research-study-phase"] ; fhir:version [ fhir:v "6.0.0-ballot2"], [ fhir:v "6.0.0-ballot2"] ; fhir:name [ fhir:v "ResearchStudyPhase"], [ fhir:v "ResearchStudyPhase"] ; fhir:title [ fhir:v "ResearchStudy Phase Code System"], [ fhir:v "ResearchStudy Phase Code System"] ; fhir:status [ fhir:v "active"], [ fhir:v "active"] ; fhir:experimental [ fhir:v "false"], [ fhir:v "false"] ; fhir:date [ fhir:v "2022-05-15T16:55:11.085+11:00"], [ fhir:v "2022-05-15T16:55:11.085+11:00"] ; fhir:publisher [ fhir:v "HL7 (FHIR Project)"], [ fhir:v "HL7 (FHIR Project)"] ; fhir:contact ( [ fhir:telecom ( [ fhir:system [ fhir:v "url" ] ; fhir:value [ fhir:v "http://hl7.org/fhir" ] ] [ fhir:system [ fhir:v "email" ] ; fhir:value [ fhir:v "fhir@lists.hl7.org" ] ] ) ] [ fhir:telecom ( [ fhir:system [ fhir:v "url" ] ; fhir:value [ fhir:v "http://hl7.org/fhir" ] ] [ fhir:system [ fhir:v "email" ] ; fhir:value [ fhir:v "fhir@lists.hl7.org" ] ] ) ] ) ; fhir:description [ fhir:v "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation."], [ fhir:v "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation."] ; fhir:jurisdiction ( [ fhir:coding ( [ fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm" ] ; fhir:code [ fhir:v "001" ] ; fhir:display [ fhir:v "World" ] ] ) ] [ fhir:coding ( [ fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm" ] ; fhir:code [ fhir:v "001" ] ; fhir:display [ fhir:v "World" ] ] ) ] ) ; fhir:caseSensitive [ fhir:v "true"] ; fhir:valueSet [ fhir:v "http://hl7.org/fhir/ValueSet/research-study-phase"] ; fhir:content [ fhir:v "complete"] ; fhir:concept ( [ fhir:code [ fhir:v "n-a" ] ; fhir:display [ fhir:v "N/A" ] ; fhir:definition [ fhir:v "Trials without phases (for example, studies of devices or behavioral interventions)." ] ] [ fhir:code [ fhir:v "early-phase-1" ] ; fhir:display [ fhir:v "Early Phase 1" ] ; fhir:definition [ fhir:v "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0." ] ] [ fhir:code [ fhir:v "phase-1" ] ; fhir:display [ fhir:v "Phase 1" ] ; fhir:definition [ fhir:v "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients." ] ] [ fhir:code [ fhir:v "phase-1-phase-2" ] ; fhir:display [ fhir:v "Phase 1/Phase 2" ] ; fhir:definition [ fhir:v "Trials that are a combination of phases 1 and 2." ] ] [ fhir:code [ fhir:v "phase-2" ] ; fhir:display [ fhir:v "Phase 2" ] ; fhir:definition [ fhir:v "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks." ] ] [ fhir:code [ fhir:v "phase-2-phase-3" ] ; fhir:display [ fhir:v "Phase 2/Phase 3" ] ; fhir:definition [ fhir:v "Trials that are a combination of phases 2 and 3." ] ] [ fhir:code [ fhir:v "phase-3" ] ; fhir:display [ fhir:v "Phase 3" ] ; fhir:definition [ fhir:v "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug." ] ] [ fhir:code [ fhir:v "phase-4" ] ; fhir:display [ fhir:v "Phase 4" ] ; fhir:definition [ fhir:v "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use." ] ] ) . # -------------------------------------------------------------------------------------
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R6 hl7.fhir.core#6.0.0-ballot2 generated on Mon, Aug 12, 2024 16:56+0800.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R5 |
|
Propose a change